HealthQuill bladder cancer
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in 27 member states and other nations.
Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults 

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

Read More
Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the USFDA has given the green light to the company’s Anktiva treatment.
Drugs Health Pharma

USFDA grants approval for ImmunityBio’s bladder cancer drug

HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Drugs Health Pharma

J&J’s metastatic bladder cancer drug gets full FDA approval

HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.

Read More
Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency.
Drugs Health Pharma

Roche’s under-the-skin cancer injection gets Britain’s nod 

HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.

Read More
gene therapy
Drugs Medical

FDA approves gene therapy for treatment of high-risk bladder cancer

The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.

Read More
X